Author: admin

Gorlin Syndrome Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Gorlin Syndrome Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gorlin Syndrome pipeline landscape. It covers the Gorlin Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gorlin Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Gorlin Syndrome Treatment Drugs @ https://www.delveinsight.com/sample-request/gorlin-syndrome-pipeline-insight

Key Takeaways from the Gorlin Syndrome Pipeline Report

  • On May 18, 2026, Cureus Researchers – A new case report titled “Extensive Flexural Basal Cell Carcinomas Revealing Gorlin-Goltz Syndrome with Marked Histopathologic Diversity” was published, highlighting the clinical complexity and diagnostic challenges associated with Gorlin Syndrome and emphasizing the need for early recognition and multidisciplinary management.
  • In January 2026- Nathalie Zeitouni initiated a study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions.DelveInsight’s Gorlin Syndrome Pipeline analysis depicts a robust space with 5+ Gorlin Syndrome companies working to develop 5+ pipeline treatment therapies.
  • DelveInsight’s Gorlin Syndrome Pipeline analysis depicts a robust space with 5+ Gorlin Syndrome companies working to develop 5+ pipeline treatment therapies.
  • The leading Gorlin Syndrome Companies such as Palvella Therapeutics Inc., PellePharm, Ascend Biopharmaceuticals and others.
  • Promising Gorlin Syndrome Pipeline Therapies such as Patidegib Topical Gel, Vismodegib, PTX-022, GDC-0449, LDE225, ASN-002, LDE225 0.25% and others.

Find out more about Gorlin Syndrome Therapeutics Assessment @ Gorlin Syndrome Preclinical and Discovery Stage Products

The Gorlin Syndrome Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Gorlin Syndrome Pipeline Report also highlights the unmet needs with respect to the Gorlin Syndrome.

Gorlin Syndrome Overview

A rare, inherited disorder that affects many organs and tissues in the body. People with this disorder have a very high risk of developing basal cell skin cancer during adolescence or early adulthood. They are also at risk of developing medulloblastoma (a type of brain cancer) and other types of cancer. Gorlin syndrome may also cause benign (not cancer) tumors in the jaw, heart, or ovaries. Other signs and symptoms include a large head and unusual facial features; small pits in the skin on the hands and feet; abnormalities of the spine, ribs, or skull; eye problems; and developmental problems. Gorlin syndrome is caused by a mutation (change) in the PTCH1 gene. Also called basal cell nevus syndrome, BCNS, NBCCS, and nevoid basal cell carcinoma syndrome.

Gorlin Syndrome Emerging Drugs

  • PTX-022: Palvella Therapeutics

PTX-022 is a novel formulation of rapamycin which leverages Palvella’s QTORIN technology. QTORIN is a proprietary and patent-pending technology that employs a specific composition of excipients that enable distribution of rapamycin into the basal keratinocytes which harbor the mutant keratin genes that are the primary defect in pachyonychia congenita. In addition to PC, QTORIN and its related technologies are being investigated in other serious, rare genodermatoses, including Gorlin Syndrome.

Explore the dynamic world of drug development with our latest Gorlin Syndrome Pipeline Insights report! Don’t miss this opportunity to stay informed—download now! @ Gorlin Syndrome Treatment Drugs

The Gorlin Syndrome pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Gorlin Syndrome with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gorlin Syndrome Treatment.
  • Gorlin Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Gorlin Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gorlin Syndrome market.

Gorlin Syndrome Companies

Palvella Therapeutics Inc., PellePharm, Ascend Biopharmaceuticals and others.

Gorlin Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous

Gorlin Syndrome Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Learn more about the emerging Gorlin Syndrome Pipeline Therapies @ Gorlin Syndrome Clinical Trials Assessment

Scope of the Gorlin Syndrome Pipeline Report

  • Coverage- Global
  • Gorlin Syndrome Companies-Palvella Therapeutics Inc., PellePharm, Ascend Biopharmaceuticals and others.
  • Gorlin Syndrome Pipeline Therapies- Patidegib Topical Gel, Vismodegib, PTX-022, GDC-0449, LDE225, ASN-002, LDE225 0.25% and others.
  • Gorlin Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Gorlin Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Gorlin Syndrome Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!” @ Gorlin Syndrome Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Gorlin-syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutics Assessment
  6. Gorlin-syndrome– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Mid Stage Products (Phase II)
  9. PTX-022: Palvella Therapeutics
  10. Early Stage Products (Phase I)
  11. Discovery Stage Products
  12. Inactive Products
  13. Gorlin-syndrome Key Companies
  14. Gorlin-syndrome Key Products
  15. Gorlin-syndrome- Unmet Needs
  16. Gorlin-syndrome- Market Drivers and Barriers
  17. Gorlin-syndrome- Future Perspectives and Conclusion
  18. Gorlin-syndrome Analyst Views
  19. Gorlin-syndrome Key Companies
  20. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/gorlin-syndrome-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/gorlin-syndrome-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gorlin Syndrome Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Parkinson Disease Clinical Trial Pipeline Gains Momentum: 150+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Parkinson’s Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

Key Takeaways from the Parkinson’s Disease Pipeline Report

  • On May 29, 2026- Biogen announced a study is to learn about the effect BIIB122 has on slowing down the worsening of PD symptoms. The study will include adults aged 30 to 80 who were diagnosed with PD within 2 years of starting the study.
  • On May 28, 2026- Gateway Institute for Brain Research initiated a phase II study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson’s Disease compared to placebo.
  • On May 27, 2026- Denali Therapeutics Inc. conducted a Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson’s Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
  • On May 27, 2026- Intra-Cellular Therapies Inc. initiated a study in patients with a diagnosis of Parkinson’s Disease consistent with the UK Parkinson’s Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
  • On May 26, 2026- Glaceum announced a phase 2a study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based on the inclusion/exclusion criteria will be assigned a subject number and randomized to one of the 3 treatment groups – 1 group receiving a placebo – in a 1:1:1 ratio. Subjects will be randomized to double-blind treatments and will receive a once-daily oral dose of the investigational product for 24 weeks according to the study protocol. Several parameters (i.e., MDS-UPDRS, CGI-C, K-NMSS, modified Hoehn-Yahr stage and SNBR) will be evaluated to assess the efficacy of vutiglabridin.
  • On May 11, 2026- Hillhurst Biopharmaceuticals Inc. initiated a phase 2a study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson’s disease (PD).
  • DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 150+ active players working to develop 200+ pipeline therapies for Parkinson’s Disease treatment.
  • The Parkinson’s Disease Companies such as Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., FAScinate Therapeutics, Cerevance, Hillhurst Biopharmaceuticals, Inc., Endurance Bio, Enterin Inc., Jazz Pharmaceuticals plc, Mthera Pharma Co., Ltd., TrueBinding, IRLAB, Annovis Bio Inc., Neuron23, Forest Hills Lab, Ventyx Biosciences, HanAll Biopharma, Lundbeck, Sanofi, ABL Bio, Contera Pharma, Eli Lilly and Company, Asceneuron SA, Allyx Therapeutics, Inc., Ventus Therapeutics and others.
  • Promising Parkinson’s Disease Pipeline Therapies such as KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others.

Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Parkinson’s Disease Clinical Trials Assessment

The Parkinson’s Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Parkinson’s Disease Pipeline Report also highlights the unmet needs with respect to the Parkinson’s Disease.

Parkinson’s Disease Overview

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement and coordination. It results from the gradual loss of dopamine-producing neurons in the brain, leading to characteristic motor and non-motor symptoms. The disease typically develops in older adults and progresses slowly, with symptoms worsening over time. Although not curable, available treatments can effectively manage symptoms and improve quality of life. Parkinson’s disease is caused by a combination of genetic and environmental factors that lead to progressive neuronal damage. Advancing age is the strongest risk factor, while inherited mutations in genes such as SNCA, LRRK2, PARK2, PINK1, and DJ-1 contribute to familial forms of the disease. Environmental exposures, including pesticides, heavy metals, and other neurotoxins, are also implicated in increasing disease risk.

Parkinson’s Disease Emerging Drugs Profile

  • Prasinezumab: Roche/Prothena Biosciences

Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease. The safety database for prasinezumab consists of data from more than 900 Parkinson’s disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. The drug is currently in Phase III of its clinical development for the treatment of patients with Parkinson’s disease.

  • Buntanetap: Annovis Bio

Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients. The drug is currently in Phase III stage of its clinical development for the treatment of patients with Parkinson’s disease.

  • NEU 411: Neuron23

NEU‑411 is an orally available, brain-penetrant small-molecule inhibitor of the kinase LRRK2, being developed by Neuron23, Inc. for Parkinson’s disease. It is designed for the subset of patients with LRRK2-driven PD whether through LRRK2 mutations or predictive SNPs where over activity of LRRK2 is believed to contribute to disease progression. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of Parkinson’s disease.

  • VTX3232: Ventyx Biosciences

VTX3232 is an oral, brain-penetrant inhibitor of the NLRP3 inflammasome, developed to target neuroinflammation in Parkinson’s disease by reducing harmful signaling from microglial activation. It crosses the blood–brain barrier, maintains plasma and cerebrospinal fluid concentrations above the inhibitory threshold for NLRP3, and thereby aims to not only ease motor/non-motor symptoms but modify underlying disease progression. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Parkinson’s disease

  • ANPD001: Aspen Neuroscience

ANPD001, developed by Aspen Neuroscience, is an investigational autologous cell-therapy for Parkinson’s disease that uses a patient’s own skin cells reprogrammed into induced pluripotent stem cells (iPSCs), then differentiated into dopaminergic neuronal precursor cells (DANPCs) for implantation. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Parkinson’s disease.

  • Lu AF28996: Lundbeck

Lu AF28996 is an investigational small-molecule therapy developed by H. Lundbeck A/S for the treatment of Parkinson’s disease. It is designed as a dual dopamine D1 and D2 receptor agonist, providing concerted stimulation of both receptor subtypes to restore dopaminergic signaling and improve motor control in patients with Parkinson’s disease. This mechanism of action aims to compensate for dopamine deficiency in the nigrostriatal pathway, thereby alleviating motor symptoms such as bradykinesia and rigidity. Lu AF28996 is formulated for oral administration, typically delivered as a capsule taken once daily. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Parkinson’s disease

Learn more about Parkinson’s Disease Drugs opportunities in our groundbreaking Research and Development projects @ Parkinson’s Disease Unmet Needs

The Parkinson’s Disease Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
  • Parkinson’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.

Parkinson’s Disease Companies

Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., FAScinate Therapeutics, Cerevance, Hillhurst Biopharmaceuticals, Inc., Endurance Bio, Enterin Inc., Jazz Pharmaceuticals plc, Mthera Pharma Co., Ltd., TrueBinding, IRLAB, Annovis Bio Inc., Neuron23, Forest Hills Lab, Ventyx Biosciences, HanAll Biopharma, Lundbeck, Sanofi, ABL Bio, Contera Pharma, Eli Lilly and Company, Asceneuron SA, Allyx Therapeutics, Inc., Ventus Therapeutics and others.

Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Parkinson’s Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Stay informed about how we’re transforming the future of Cardiovascular Diseases @ Parkinson’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Parkinson’s Disease Pipeline Report

  • Coverage– Global
  • Parkinson’s Disease Companies– Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., FAScinate Therapeutics, Cerevance, Hillhurst Biopharmaceuticals, Inc., Endurance Bio, Enterin Inc., Jazz Pharmaceuticals plc, Mthera Pharma Co., Ltd., TrueBinding, IRLAB, Annovis Bio Inc., Neuron23, Forest Hills Lab, Ventyx Biosciences, HanAll Biopharma, Lundbeck, Sanofi, ABL Bio, Contera Pharma, Eli Lilly and Company, Asceneuron SA, Allyx Therapeutics, Inc., Ventus Therapeutics and others.
  • Parkinson’s Disease Pipeline Therapies- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others
  • Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Parkinson’s Disease Pipeline on our website @ Parkinson’s Disease Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Parkinson’s Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Parkinson’s Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Prasinezumab: Roche/ Prothena Biosciences
  9. Mid Stage Products (Phase II)
  10. NEU 411: Neuron23
  11. Early Stage Products (Phase I)
  12. Lu AF28996: Lundbeck
  13. Preclinical and Discovery Stage Products
  14. Inactive Products
  15. Parkinson’s Disease Key Companies
  16. Parkinson’s Disease Key Products
  17. Parkinson’s Disease- Unmet Needs
  18. Parkinson’s Disease- Market Drivers and Barriers
  19. Parkinson’s Disease- Future Perspectives and Conclusion
  20. Parkinson’s Disease Analyst Views
  21. Parkinson’s Disease Key Companies
  22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson Disease Clinical Trial Pipeline Gains Momentum: 150+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Renal Cell Carcinoma Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Renal Cell Carcinoma Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape @ Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Renal Cell Carcinoma Pipeline Report

  • On May 29, 2026- Merck Sharp & Dohme LLC announced a phase 3 study is to learn if people who receive belzutifan and zanzalintinib live longer. A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
  • On May 22, 2026- Oncorena AB initiated a phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 75 patients and is conducted in 3 parts. The study will consist of 3 parts: Part A – an intra-patient dose escalation part, followed by a dose exposure (Part B), followed by a dose expansion (Part C).
  • On May 22, 2026- Pfizer conducted a phase 1B/2 study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them
  • On May 20, 2026- M.D. Anderson Cancer Center conducted a Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
  • DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Renal Cell Carcinoma treatment.
  • The leading Renal Cell Carcinoma Companies such as Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others.
  • Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.

Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs @ Renal Cell Carcinoma Clinical Trials Assessment

The Renal Cell Carcinoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Renal Cell Carcinoma Pipeline Report also highlights the unmet needs with respect to the Renal Cell Carcinoma.

Renal Cell Carcinoma Overview

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, originating from the lining of the renal tubules in the kidney. It accounts for approximately 85–90% of all kidney cancers. RCC often develops silently in the early stages, and many cases are discovered incidentally during imaging studies performed for other conditions. Common symptoms in advanced disease may include hematuria, flank pain, weight loss, fatigue, and a palpable abdominal mass. Several histological subtypes exist, with clear cell renal cell carcinoma being the most common.

Renal Cell Carcinoma Emerging Drugs Profile

  • Casdatifan: Arcus Biosciences

Casdatifan (AB521) is an investigational oral small-molecule hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor being developed for clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. HIF-2α acts as a “master switch” that activates multiple genes under low-oxygen conditions, and in most patients with ccRCC this pathway remains abnormally activated because of VHL pathway abnormalities, promoting tumor growth and survival. Casdatifan is designed to provide deep and durable inhibition of the HIF-2α pathway, thereby blocking tumor proliferation, angiogenesis, treatment resistance, and cancer cell survival. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Renal Cell Carcinoma.

  • BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.

BL-B01D1 is a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors, including renal cell carcinoma and other urinary system tumors. The drug is designed to simultaneously target epidermal growth factor receptor (EGFR) and HER3 expressed on tumor cells and deliver a topoisomerase I inhibitor payload directly into cancer cells, thereby promoting selective tumor cell killing while limiting systemic toxicity. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Renal Cell Carcinoma.

  • Orellanine: Oncorena AB

Orellanine is a first-in-class investigational therapy being developed for metastatic renal cell carcinoma, particularly clear-cell and papillary renal cell carcinoma. Orellanine is a toxin originally derived from mushrooms of the Cortinarius family and is being developed as an organ-specific chemotherapy for kidney cancer. The mechanism of action involves selective uptake into renal cancer cells through transporters highly expressed on kidney tumor cells, where it induces oxidative stress, disrupts mitochondrial function, down-regulates intracellular defense mechanisms, and ultimately triggers apoptosis and tumor cell death. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Renal Cell Carcinoma.

  • XmAb819: Xencor, Inc.

XmAb819 is a first-in-class, tumor-targeted XmAb® 2+1 bispecific antibody being developed for patients with advanced clear cell renal cell carcinoma (ccRCC). The drug is designed to target ENPP3, an antigen highly expressed on kidney cancer cells, while simultaneously engaging CD3 on T cells to activate targeted immune-mediated killing of tumor cells. According to the company, the XmAb 2+1 format contains two ENPP3 binding domains and one CD3 binding domain, enabling selective binding to tumor cells with high antigen density while potentially sparing normal tissues. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Renal Cell Carcinoma.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs

The Renal Cell Carcinoma Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cell Carcinoma Treatment.
  • Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cell Carcinoma market.

Renal Cell Carcinoma Companies

Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Renal Cell Carcinoma Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Transform your understanding of the Renal Cell Carcinoma Pipeline! @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Renal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Renal Cell Carcinoma Companies- Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others.
  • Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
  • Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Renal Cell Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Casdatifan: Arcus Biosciences
  9. Mid Stage Products (Phase II)
  10. BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.
  11. Early Stage Products (Phase I)
  12. XmAb819: Xencor, Inc.
  13. Preclinical and Discovery Stage Products
  14. Inactive Products
  15. Renal Cell Carcinoma Key Companies
  16. Renal Cell Carcinoma Key Products
  17. Renal Cell Carcinoma – Unmet Needs
  18. Renal Cell Carcinoma – Market Drivers and Barriers
  19. Renal Cell Carcinoma – Future Perspectives and Conclusion
  20. Renal Cell Carcinoma Analyst Views
  21. Renal Cell Carcinoma Key Companies
  22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Renal Cell Carcinoma Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Idiopathic Pulmonary Fibrosis Pipeline? @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight

Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report

  • On June 01, 2026- Contineum Therapeutics initiated a phase 2 study to evaluate the efficacy, safety, tolerability, and PK of PIPE-791 in subjects with a diagnosis of Idiopathic Pulmonary Fibrosis with or without background treatment. The treatment period is 26 weeks and full study duration is up to 36 weeks including Screening and Follow-Up. Approximately 324 subjects will be enrolled into one of three treatment arms, PIPE-791 Dose A, PIPE-791 Dose B, or placebo.
  • On May 27, 2026- Boehringer Ingelheim conducted a phase IIa study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution computed tomography (HRCT) scan. The purpose of this study is to find out if a medicine called BI 765423 can improve lung function in people with IPF. The study will compare BI 765423 with a placebo to see if there is a difference in lung capacity after 3 months of treatment and will also look at changes in certain markers related to lung health.
  • On May 13, 2026- Dragonboat Biopharmaceutical Company Limited initiated a Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.
  • On May 07, 2026- Rein Therapeutics announced a research study is to evaluate LTI-03 including: its safety, whether it causes side effects, whether it improves lung scarring, and whether it improves IPF symptoms. LTI-03 will be compared to placebo in patients diagnosed with IPF within the last 5 years. Patients on a stable dose of nintedanib, pirfenidone, or nerandomilast (if available by prescription) may participate.
  • On May 01, 2026- Vicore Pharma AB conducted a ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.
  • DelveInsight’s Idiopathic Pulmonary Fibrosis Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
  • The leading Idiopathic Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.
  • Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, and others.

Want to know which companies are leading innovation in Idiopathic Pulmonary Fibrosis? @ Idiopathic Pulmonary Fibrosis Clinical Trials Assessment

The Idiopathic Pulmonary Fibrosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Idiopathic Pulmonary Fibrosis Pipeline Report also highlights the unmet needs with respect to the Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).

Idiopathic Pulmonary Fibrosis Emerging Drugs Profile

  • BMS-986278: Bristol-Myers Squibb

Admilparant (BMS-986278) is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA1 are involved in the pathogenesis of pulmonary fibrosis. A preclinical in vitro and in vivo study found that antagonizing LPA1 may be beneficial in treating lung injury and fibrosis. Currently, the drug is in the Phase III stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

  • ENV-101: Endeavor BioMedicine

ENV-101 (Endeavor BioMedicine) is an investigational small-molecule therapy being developed by Endeavor BioMedicine for fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It is designed to selectively inhibit pathways involved in fibrosis progression, aiming to reduce excessive tissue scarring and preserve lung function. The drug is currently in early clinical development, with studies focused on evaluating its safety, tolerability, and anti-fibrotic activity. Preclinical findings have shown potential to modulate key drivers of fibrosis, supporting its advancement into human trials. Overall, ENV-101 represents a targeted approach that could offer improved disease control compared to existing symptomatic treatments for fibrotic lung disorders. Currently, the drug is in the Phase II stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

  • AZD8965: AstraZeneca

AZD8965 (AstraZeneca) is an investigational small-molecule therapy being developed by AstraZeneca for idiopathic pulmonary fibrosis (IPF). It functions as an arginase (ARG1/ARG2) inhibitor, targeting metabolic pathways linked to fibrosis progression. The drug is currently in Phase I clinical development, with ongoing studies evaluating its safety, tolerability, and pharmacokinetics in healthy participants. By modulating arginase activity, AZD8965 aims to reduce fibrotic remodeling and inflammation, representing a novel mechanism compared to existing IPF therapies. If successful, it could provide a new targeted treatment approach for fibrotic lung diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

If you’re tracking ongoing Idiopathic Pulmonary Fibrosis Clinical trials, this press release is a must-read @ Idiopathic Pulmonary Fibrosis Treatment Drugs

The Idiopathic Pulmonary Fibrosis Pipeline report provides insights into:-

  • The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
  • Idiopathic Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

Idiopathic Pulmonary Fibrosis Companies

Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.

Idiopathic Pulmonary Fibrosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as,

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

The Idiopathic Pulmonary Fibrosis Pipeline Report covers it all @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report

  • Coverage- Global
  • Idiopathic Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.
  • Idiopathic Pulmonary Fibrosis Pipeline Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, and others.
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Idiopathic Pulmonary Fibrosis Treatment landscape in this detailed analysis @ Idiopathic Pulmonary Fibrosis Emerging Drugs and Major Players

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Idiopathic Pulmonary Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutics Assessment
  6. Idiopathic Pulmonary Fibrosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. BMS-986278: Bristol-Myers Squibb
  9. Mid Stage Products (Phase II)
  10. ENV-101: Endeavor BioMedicine
  11. Early Stage Products (Phase I)
  12. AZD8965 AstraZeneca
  13. Preclinical and Discovery Stage Products
  14. Inactive Products
  15. Idiopathic Pulmonary Fibrosis Key Companies
  16. Idiopathic Pulmonary Fibrosis Key Products
  17. Idiopathic Pulmonary Fibrosis- Unmet Needs
  18. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
  19. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
  20. Idiopathic Pulmonary Fibrosis Analyst Views
  21. Idiopathic Pulmonary Fibrosis Key Companies
  22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | DelveInsight

Graft versus Host Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 45+ Key Companies | DelveInsight

elveInsight’s, “Graft versus host disease Pipeline Insight 2026” report provides comprehensive insights about 45+ Graft Versus Host Disease Companies and 50+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Graft versus Host Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Graft versus Host Disease Pipeline? @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight

Key Takeaways from the Graft versus Host Disease Pipeline Report

  • On June 01, 2026- Incyte Corporation initiated a phase 3 study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
  • On May 29, 2026- Beth Israel Deaconess Medical Center conducted a research study is a way of gaining new knowledge about the treatment of patients with cGVHD. This research study is evaluating a drug called abatacept. Abatacept is a drug that alters and suppresses the immune system. Abatacept is approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe active rheumatoid arthritis in adults and of severe juvenile idiopathic arthritis (JIA) in patients who have failed prior therapy with disease-modifying anti-rheumatic drugs (DMARDs).
  • On May 28, 2026- Novartis Pharmaceuticals initiated a study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).
  • On May 27, 2026- Sanofi announced a phase 4 study is to verify the pharmacokinetics, efficacy, and safety of belumosudil mesylate tablets in Chinese adolescent participants (aged from 12 to less than 18) with cGVHD who have had an inadequate response to glucocorticoids or other systemic therapies. Participants will receive treatment with belumosudil tablets 200 mg once daily in 28-day cycles during the study.
  • On May 26, 2026- Cynata Therapeutics Limited announced a phase II study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive ongoing CS therapy as appropriate per institutional guidelines. Subjects will have study visits up to Day 100 during the Primary Evaluation Period. During the Follow-Up Period, subjects will have study visits up to 24 months.
  • DelveInsight’s Graft Versus Host Disease pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Graft Versus Host Disease treatment.
  • The leading Graft Versus Host Disease Companies such as Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.
  • Promising Graft Versus Host Disease Therapies such as Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.

Want to know which companies are leading innovation in Graft versus Host Disease? @ Graft versus Host Disease Clinical Trials Assessment

The Graft versus Host Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Graft versus Host Disease Pipeline Report also highlights the unmet needs with respect to the Graft versus Host Disease.

Graft versus Host Disease Overview

Graft versus host disease (GVHD) is a serious complication that occurs when donor immune cells attack the recipient’s body following an allogeneic stem cell or bone marrow transplant. This condition arises because the donor’s immune cells, recognizing the recipient’s cells as foreign, initiate an immune response against them. GVHD primarily involves T-cells from the donor graft and can be classified into two main types: acute and chronic. Acute GVHD typically develops within the first 100 days post-transplant, manifesting through symptoms like skin rashes, jaundice, liver enzyme abnormalities, and diarrhea.

Graft versus host disease Emerging Drugs

  • Itolizumab: Equillium

Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab was launched in India in 2013 under the brand name ALZUMAB. Itolizumab received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome. The drug is currently in Phase III clinical development for the treatment of acute graft-versus-host disease (aGVHD).

  • ABSK021: Abbisko Therapeutics

Pimicotinib (ABSK021), which was independently developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Abbisko is actively exploring the potential of pimicotinib in treating other indications including many types of solid tumors in clinic, and has obtained approval from NMPA to conduct a Phase II clinical study in chronic graft-versus-host disease. Currently, the drug is in the Phase II stage of its development for the treatment of Chronic Graft Versus Host Disease.

  • SYN-004: Theriva Biologics

SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection. Antibiotic-mediated damage of the gut microbiome in allogeneic HCT recipients has been strongly associated with adverse outcomes including CDI, vancomycin-resistant enterococci (VRE) colonization and potentially fatal bacteremia and aGVHD. Currently, the drug is in the Phase I/II stage of its development for the treatment of Graft versus host disease.

  • SER-155: Seres Therapeutics

SER-155 is an oral, investigational therapeutic comprising a fermented consortium of commensal bacteria, specifically designed to support immunocompromised patients. Its primary mechanism of action involves augmenting crucial microbiome functions that contribute to improved survival and reduced risks of infections and graft versus host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). By leveraging insights from human clinical data, SER-155 aims to fortify the gut microbiome, enhance immune function, and protect against gastrointestinal infections and bacteremia. This multifaceted approach may offer a promising solution for patients facing the challenges of stem cell transplantation. Currently, the drug is in Phase I stage of its clinical trial for the treatment of GvHD.

If you’re tracking ongoing Graft versus Host Disease Clinical trials, this press release is a must-read @ Graft versus Host Disease Treatment Drugs

Graft versus Host Disease Companies

Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.

The Graft versus Host Disease Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Graft versus Host Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft versus Host Disease Treatment.
  • Graft versus Host Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Graft versus Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft versus Host Disease market.

GVHD Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Graft versus host disease products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Graft versus host disease Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

From emerging drug candidates to competitive intelligence, the Graft versus Host Disease Pipeline Report covers it all @ Graft versus Host Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Graft versus Host Disease Pipeline Report

  • Coverage- Global
  • Graft versus Host Disease Companies- Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.
  • Graft Versus Host Disease Therapies- Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.
  • Graft versus Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Graft versus Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Graft versus Host Disease treatment landscape in this detailed analysis @ Graft versus Host Disease Emerging Drugs and Major Players

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Graft versus host disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Graft versus host disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Itolizumab: Equillium
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ABSK021: Abbisko Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. SER-155: Seres Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Graft versus host disease Key Companies
  21. Graft versus host disease Key Products
  22. Graft versus host disease- Unmet Needs
  23. Graft versus host disease- Market Drivers and Barriers
  24. Graft versus host disease- Future Perspectives and Conclusion
  25. Graft versus host disease Analyst Views
  26. Graft versus host disease Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graft versus Host Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 45+ Key Companies | DelveInsight

Hanley Investment Group Chief Operations Officer Tiffanie Farr Named to GlobeSt. 2026 Women of Influence

CORONA DEL MAR, Calif. — Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, announced today that Tiffanie Farr, chief operations officer, has been named to GlobeSt.’s 2026 Women of Influence, recognizing her national leadership, innovation and measurable impact on the commercial real estate industry.

Since 1983, this award has recognized a growing number of commercial real estate female professionals for their remarkable achievements. The individual honorees have personally impacted the market and have significantly driven the industry to new heights via their outstanding successes. The 2026 Women of Influence were selected by GlobeSt.’s esteemed advisory board and senior editors based on how well they achieved goals and displayed ingenuity in regard to their nomination category; how impactful their work has been; how dedicated the nominee has been to furthering the development of their field and the role of women within it; and the nominee’s personal commitment to the highest ethical standards, service and excellence.

“This year’s honorees have executed significant deals, introduced bold initiatives, and expanded the reach of their organizations,” says Natalie Dolce, editor-in-chief of GlobeSt.com. “In addition to their professional accomplishments, they’ve spent countless hours mentoring others and advocating for meaningful causes. The depth and quality of submissions this year were truly inspiring and highlight the powerful strides women continue to make in an industry historically defined by tradition.”

Farr has spent more than two decades strengthening the operational foundation of commercial real estate brokerage. As chief operations officer for Hanley Investment Group, she has modernized the firm’s systems, elevated its data-driven national platform and helped drive record‑breaking performance through some of the industry’s most uncertain cycles. Farr joined Hanley Investment Group in April 2020, just weeks after COVID-19 shut down offices nationwide. She immediately stabilized operations, implemented remote‑work systems and led the development of the technological infrastructure that enabled the firm to remain fully functional and outperform the market. Her decisive leadership during crisis set the foundation for the firm’s next six years of growth.

In 2025, Farr oversaw one of the most significant operational advancements in the firm’s history: the implementation of a unified workforce management system that consolidated six separate HR, payroll, benefits, onboarding and compliance tools into a single platform. The system eliminated manual processes, reduced errors, improved transparency and created a scalable foundation for future expansion.

Under her operational direction, Hanley achieved the highest sales volume in its 20-year history in 2025, closing $1.11 billion in total sales, 208 transactions across 33 states and 3.2 million square feet, including 94 closings in 90 days at the end of 2025. She also oversaw the hiring of 10 new team members, including the firm’s first female investment advisor, and strengthened organizational structure to ensure the “right person in the right seat.”

Farr’s leadership extends beyond operations. She has strengthened the relationship between sales and marketing, championed cross-departmental collaboration and fostered a culture where contributions are recognized and team members feel valued. Her mentorship has directly supported the advancement of women within the firm, including the transition of two women into transaction‑team roles.

“Tiffanie’s leadership has elevated every part of our organization,” said Ed Hanley, president of Hanley Investment Group. “Her ability to strengthen our people, systems and culture continues to drive Hanley’s success at every level and support our long‑term growth.”

The 2026 Women of Influence honorees will be recognized at GlobeSt.’s annual awards dinner in Denver on July 13, 2026, and profiled in a feature article on GlobeSt.com on July 7.

About Hanley Investment Group

Hanley Investment Group Real Estate Advisors is a real estate brokerage and advisory services company with a transaction track record of $12.9 billion, specializing in the sale of retail properties nationwide. The firm’s expertise, proven track record spanning more than 20 years, and dedication to putting clients’ needs first set it apart in the industry. Hanley Investment Group creates value by delivering exceptional results through property-specific marketing strategies, cutting-edge technology and local market knowledge. Hanley Investment Group’s relationships with investors, developers, institutions, franchisees, brokers and 1031 exchange buyers translate into maximum exposure and pricing for each property. With unmatched service, Hanley Investment Group has redefined the experience of selling retail investment properties. For more information, visit hanleyinvestmentgroup.com.

Media Contact
Company Name: Hanley Investment Group Real Estate Advisors
Contact Person: Heidi Mayeda, Marketing Manager
Email: Send Email
Phone: 949.585.7606
Address:3500 East Coast Highway, Suite 100
City: Corona del Mar
State: https://hanleyinvestmentgroup.com/
Country: United States
Website: https://hanleyinvestmentgroup.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hanley Investment Group Chief Operations Officer Tiffanie Farr Named to GlobeSt. 2026 Women of Influence

Automotive Collision Repair Market to Reach USD 267.86 Billion by 2035, Rising Vehicle Ownership, Insurance Claim Growth, and Advanced Repair Technology Adoption

“Automotive Collision Repair Market Outlook 2026 to 2035”
“Automotive Collision Repair Market Size, Share & Growth Analysis Report — Industry Trends & Forecast to 2035” (Report ID: MRFR/AT/20547-HCR, 128 pages) — report covers segmentation by service type, vehicle type, repair technique, end user, and region.

New York, NY – June 3, 2026 – The global Automotive Collision Repair Market was valued at USD 204.1 billion in 2024 and is projected to grow from USD 209.21 billion in 2025 to USD 267.86 billion by 2035, registering a CAGR of 2.5% over the forecast period, according to the latest analysis by Market Research Future (MRFR).

Growth is anchored in steadily rising global vehicle ownership — with an estimated 1.4 billion cars now on the world’s roads — combined with growing insurance penetration for collision coverage, increasing vehicle complexity requiring specialized repair services, and accelerating adoption of advanced repair technologies such as automated systems, high-strength composite materials, and AI-driven cost estimation.

North America remains the clear market leader with approximately 45% of global share, while Asia-Pacific is emerging rapidly at around 20% share as rising disposable incomes and urbanization drive both vehicle sales and accident-related repair demand.

Download Sample PDF – https://www.marketresearchfuture.com/sample_request/22147

Key Market Drivers

  1. Increasing Vehicle Ownership and Accident Frequency

Global vehicle ownership has surpassed an estimated 1.4 billion units, creating a sustained and expanding baseline of collision repair demand. As more individuals across developed and developing economies acquire vehicles, accident frequency rises proportionately, particularly in urban corridors where traffic density is highest. The increasing complexity of modern vehicles — equipped with advanced driver-assistance systems (ADAS), sensors, cameras, and radar arrays — means that even minor collisions require specialized diagnostic and repair services, driving both volume and revenue per repair event.

  1. Rising Insurance Claims for Collision Repairs

The expansion of comprehensive vehicle insurance coverage is a direct demand multiplier for the Automotive Collision Repair Market. As more drivers opt for policies that include collision coverage, the frequency of insurance-backed repair claims rises correspondingly. Insurance companies are increasingly partnering with certified repair networks — including national chains such as Caliber Collision (US), Gerber Collision & Glass (US), and Service King (US) — to create integrated claims-processing and repair-service ecosystems. These partnerships streamline the repair workflow and create consistent, high-volume referral channels for collision repair facilities.

  1. Technological Innovations in Repair Techniques

Advances in repair technology are both expanding the addressable market and raising average repair values. The adoption of aluminum, ultra-high-strength steel, and composite materials in modern vehicle manufacturing requires specialized repair methods and equipment investment. Integration of AI in repair cost estimation and workflow management is reducing turnaround times. The Advanced Repair segment, which encompasses automated systems, high-tech materials, and advanced diagnostics, is projected to reach USD 85.0 billion by 2035, reflecting its status as the fastest-growing repair technique category. Meanwhile, mobile repair units are emerging as a convenience-driven growth channel, enabling on-site repairs that reduce vehicle downtime.

  1. Regulatory Compliance and Safety Standards

Governments worldwide are enforcing increasingly stringent vehicle safety standards, compelling repair shops to adhere to exacting specifications and invest in certified equipment. Environmental regulations governing waste disposal and VOC emissions from paint and refinishing processes are further reshaping shop-level operations. Repair facilities that achieve and maintain regulatory certification gain a competitive advantage, as insurance partners and fleet operators preferentially direct work to compliant, certified shops. This compliance imperative is consolidating demand toward professional repair networks at the expense of informal or uncertified operators.

Ask for Required Customization – https://www.marketresearchfuture.com/ask_for_customize/22147

Market Segmentation Highlights

By Service Type

  • Body Repair (Largest Segment — USD 80.0 Billion in 2024): The dominant service category, encompassing framework straightening, dent removal, panel replacement, and structural realignment. Driven by consistent demand from collision events that compromise vehicle safety and aesthetics.
  • Paint Repair (Fastest-Growing): Projected to reach USD 65.0 Billion by 2035. Growth is propelled by consumer demand for aesthetic restoration, rising popularity of custom finishes, and eco-friendly waterborne paint technologies that align with sustainability mandates.
  • Mechanical Repair: Addresses drivetrain, suspension, and mechanical damage resulting from collision events. Demand grows alongside vehicle complexity and the need for ADAS recalibration post-collision.
  • Glass Replacement (Emerging): Valued between USD 34.1 and USD 42.86 Billion in 2024. Rapidly expanding due to heightened safety standards and the proliferation of embedded ADAS cameras and sensors in windshields that require precise, certified replacement.

By Vehicle Type

  • Passenger Cars (Largest — Projected USD 105.0 Billion by 2035): The dominant vehicle segment due to the sheer volume of passenger cars globally. Consistent collision frequency across urban and highway environments generates reliable, high-volume repair demand across all service categories.
  • Light Trucks (Fastest-Growing): Expanding share driven by increasing consumer and commercial preference for SUVs, pickups, and light-duty trucks. Higher vehicle values and more complex structural designs drive elevated per-repair revenue.
  • Commercial Vehicles: Steady demand from fleet operators focused on minimizing vehicle downtime and maintaining road safety compliance.
  • Motorcycles (Emerging): Growing in prominence as urbanization and the motorcycle-ownership community expands, particularly across Asia-Pacific markets.

By Repair Technique

  • Traditional Repair (Largest Segment): Encompasses established manual labor techniques and conventional processes widely trusted by consumers. Remains dominant due to its extensive installed base of skilled technicians and broad facility availability.
  • Advanced Repair (Fastest-Growing — Projected USD 85.0 Billion by 2035): Leverages cutting-edge automated systems, high-tech composite materials, and advanced diagnostics. Reduces turnaround times while improving repair precision. Increasingly specified by insurance partners and premium vehicle OEMs.
  • Mobile Repair: An emerging convenience-driven channel enabling on-site repair services that eliminate shop visits for minor damage. Particularly attractive to fleet owners and time-sensitive individual consumers.

By End User

  • Individual Owners (Largest — USD 102.05 Billion in 2024): The dominant end-user group, representing the primary consumer base for collision repair services. Prioritize accessible, quality-assured repair from certified shops with established reputations.
  • Fleet Owners (Fastest-Growing — USD 61.23 Billion in 2024): The most rapidly expanding end-user segment as commercial vehicle utilization rises globally. Fleet operators prioritize speed, cost-effectiveness, and uptime minimization, creating demand for streamlined, technology-enabled repair cycles and ongoing shop partnerships.
  • Insurance Companies: Act as a critical referral and payment channel, directing repair volume to certified network partners. Increasing integration between insurers and repair chains is reshaping procurement dynamics across the market.

Browse Premium Research Details – https://www.marketresearchfuture.com/reports/automotive-collision-repair-market-22147

 

Key Market Participants

The Automotive Collision Repair Market is moderately fragmented, with a mix of large national chains and smaller independent shops competing across geographies. National chains are differentiating through acquisitions, insurance partnerships, digital transformation, and technology-enabled repair capabilities.

  • Caliber Collision (US): One of the largest collision repair networks in North America. Expanding footprint through acquisitions. Opened a new state-of-the-art facility in California in August 2025 to enhance service capacity and improve turnaround times (calibercollision.com).
  • Service King (US): Emphasizes customer-centric solutions and digital transformation. In September 2025, launched a new mobile app allowing customers to schedule repairs, track progress, and communicate directly with service representatives.
  • Gerber Collision & Glass (US): Leveraging insurance partnerships to create an integrated claims-processing and repair-service model. In July 2025, entered a strategic partnership with a leading insurance provider for integrated claims processing (gerbercollision.com).
  • ABRA Auto Body & Glass (US): Major multi-location repair operator serving individual and fleet customers across the United States.
  • Maaco (US): National franchise network focused on accessible paint and body repair services for individual vehicle owners.
  • Fix Auto (CA): Leading collision repair franchise network operating across Canada and internationally, with strong insurer-referral relationships.
  • Bodyshop (GB): Prominent UK-based collision repair chain serving individual owners and insurance company referrals.
  • Carstar (US): Franchise collision repair network with broad geographic coverage across North America.
  • Nissan Collision Repair (JP): OEM-affiliated collision repair network operating across Japan and Asia-Pacific, specializing in Nissan and Infiniti vehicle platforms.

Recent Industry Developments

  • Caliber Collision (August 2025): Announced the opening of a new state-of-the-art facility in California, expected to enhance service capacity and improve customer turnaround times, with investment in advanced repair technology to attract technology-focused consumers.
  • Service King (September 2025): Launched a new mobile application enabling customers to schedule repairs, track repair progress in real time, and communicate directly with service representatives — underscoring the industry’s digital transformation trend.
  • Gerber Collision & Glass (July 2025): Entered a strategic partnership with a leading insurance provider to offer fully integrated claims processing and repair services, reflecting the broader trend toward vertical integration in the collision repair industry.
  • BASF (July 2023): Announced the expansion of its automotive refinish system, signaling sustained innovation in product formulations for collision repair coatings and materials.
  • LKQ Corporation (April 2023): Acquired a regional automotive parts retailer, broadening its collision repair parts supply offerings and reinforcing its position in the aftermarket parts ecosystem.
  • DuPont and PPG Industries: Continued advancement of sustainable automotive refinish product lines, with eco-friendly formulations gaining traction across North American and European repair markets.
  • Magna International: Making ongoing strides in integrating advanced technology into collision repair processes, with expected improvements in repair efficiency and reduction in average cycle times.

 

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com/reports/automotive-collision-repair-market-22147

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Automotive Collision Repair Market to Reach USD 267.86 Billion by 2035, Rising Vehicle Ownership, Insurance Claim Growth, and Advanced Repair Technology Adoption

Bearing Isolators Market to Reach USD 3.18 Billion at a 5.74% CAGR by 2035, Driven by VFD Proliferation, Fugitive-Emission Mandates, and ASEAN Manufacturing Expansion

“Bearing Isolators Market Outlook 2026 to 2035”
The report — “Bearing Isolators Market Size, Share & Growth Analysis Report 2026: Trends & Industry Forecast to 2035” (Report ID: MRFR/EnP/23596-HCR, 128 pages) covers segmentation by type, material, application, end-user industry, and region.

New York, NY – June 3, 2026 – The global Bearing Isolators Market reached an estimated USD 1.93 billion in 2025 and is projected to grow from USD 2.04 billion in 2026 to USD 3.18 billion by 2035, registering a CAGR of 5.74% over the forecast period, according to Market Research Future (MRFR).

Growth is anchored in two converging forces: the global rollout of variable-frequency drives (VFDs) across industrial motors, which introduces shaft-voltage discharge that degrades conventional lip seals, and tightening fugitive-emission regulations under U.S. EPA Method 21 and the EU Industrial Emissions Directive (Directive 2024/1785). Both catalysts are pushing plant operators to replace legacy rotating lip seals with non-contacting bearing isolators that eliminate wear and reduce bearing vapor emission pathways.

Additive-manufactured composite isolators are approximately 30% lighter than conventional bronze parts, enabling novel applications in offshore wind nacelles and high-speed turbomachinery. Approximately USD 450 million in efficiency gains have been delivered through the U.S. Department of Energy’s aBetter Plants Program in facility upgrades where non-contacting bearing isolator modifications feature prominently.

Ask for Sample PDF – https://www.marketresearchfuture.com/sample_request/25228

Key Market Drivers

  1. VFD Proliferation and Shaft-Voltage Damage (+1.3% CAGR Impact)

According to the International Energy Agency, electric motors consume over 40% of global electricity, driving regulatory pushes for high-efficiency standards such as IE3 and IE4 that increasingly rely on VFD control. Each VFD-equipped motor generates common-mode voltage pulses causing electrical discharge machining, where current arcs through bearings, pitting raceways and degrading lubricant. Premium engineering specifications increasingly mandate non-contacting bearing isolator solutions in NEMA and IEC motor frames above 50 hp. Federal efficiency initiatives such as the U.S. DOE Better Plants Program drive large-scale facility upgrades where grounding and isolating systems feature prominently.

  1. Fugitive-Emission Regulatory Tightening (+1.1% CAGR Impact)

The revised EU Industrial Emissions Directive (Directive 2024/1785) and U.S. EPA Method 21 protocols are forcing refineries and chemical plants to limit volatile organic compound (VOC) emissions from rotating equipment. Plants are adopting a holistic containment approach: traditional contact lip seals on centrifugal pumps wear down shaft surfaces and fail, leading to oil leaks and costly unplanned maintenance. Bearing isolators that demonstrably reduce Scope 1 fugitive emissions are increasingly specified by publicly listed oil and gas operators subject to investor ESG scrutiny.

  1. ASEAN Greenfield Manufacturing Build-Out (+0.9% CAGR Impact)

Foreign direct investment into ASEAN manufacturing rose an estimated 135% in 2024, translating directly into new pump, compressor, and turbine installations that specify bearing isolators from commissioning. Vietnam, Indonesia, and Thailand are each adding petrochemical and LNG-processing capacity requiring thousands of non-contacting bearing isolator pump units annually through 2030.

  1. Offshore Wind Nacelle Expansion (+0.7% CAGR Impact)

The IEA tracks cumulative offshore wind capacity additions projected to grow by roughly 140 GW globally between 2024 and 2030, with annual market additions averaging 15–20 GW. Each nacelle houses high-speed generator bearings exposed to salt-laden marine air and moisture ingress. Composite and hybrid non-contacting bearing isolator seals are being adopted to protect internal environments without sacrificing weight.

Ask for Required Customization – https://www.marketresearchfuture.com/ask_for_customize/25228

Market Segmentation Highlights

By Type

Non-Contact Bearing Isolators: Dominant segment with 50.2% market share in 2025. Labyrinth seal geometry delivers a mean time between replacement (MTBR) exceeding 10 years, versus 18–24 months for conventional rotating lip seals (Hydraulic Institute, pumps.org).

Magnetic Bearing Isolators: Fastest-growing type at a 6.32% CAGR (2026–2035). Permanent-magnet face-seal design maintains hermetic barrier regardless of shaft speed — essential for turbine applications where micro-leakage of process gas is unacceptable.

Contact Bearing Isolators: USD 0.42 billion in 2025 revenue, serving legacy motor replacement in cost-sensitive plants.

Hybrid Bearing Isolators: USD 0.18 billion in 2025 revenue, favored in misalignment-tolerant mining applications.

By Material

Metallic (Bronze, Stainless, Aluminum): Leading segment with 54.4% share in 2025. Favored for dimensional stability at temperatures exceeding 300 °C.

Composite / Hybrid Materials: Fastest-growing material segment at a 6.78% CAGR (2026–2035). Additive-manufactured units are ~30% lighter than conventional bronze, enabling complex labyrinth geometries impossible with traditional casting.

Polymer (PTFE, PEEK): USD 0.16 billion in 2025 revenue, valued for chemical resistance in aggressive-media pump service.

By Application

Pumps: USD 0.53 billion in 2025 revenue — the largest application segment, driven by API 610 and ISO 13709 pump specifications increasingly mandating non-contacting bearing isolator technology during scheduled turnarounds (API, api.org).

Turbines (Steam, Gas, Wind): Fastest-growing application at a 6.76% CAGR (2026–2035), propelled by offshore wind expansion and gas-turbine fleet growth.

Motors: Growing at a 5.54% CAGR (2026–2035), driven by VFD-induced shaft-voltage protection requirements.

Compressors: USD 0.22 billion in 2025 revenue, supported by LNG, hydrogen, and carbon-capture compression demand.

Gearboxes: Growing at a 5.31% CAGR (2026–2035), primarily in pulp-and-paper and sugar-milling applications.

By End-User Industry

Oil & Gas: Largest end-user with 25.6% market share in 2025, driven by upstream, midstream, and refining pump fleets.

Power Generation: Fastest-growing end-user vertical at a 6.89% CAGR (2026–2035), as steam and gas turbine operators accelerate split-design bearing isolator retrofit campaigns to meet emissions targets.

Chemical & Petrochemical: USD 0.37 billion in 2025 revenue, underpinned by fugitive-emission compliance and corrosion-resistance requirements.

Water & Wastewater: Growing at a 5.62% CAGR (2026–2035), driven by municipal infrastructure upgrade cycles.

Mining & Metals: USD 0.14 billion in 2025 revenue, focused on slurry-pump bearing protection in harsh environments.

Browse Premium Research Insights – https://www.marketresearchfuture.com/reports/bearing-isolators-market-25228

 

Key Market Participants

The Bearing Isolators Market is moderately concentrated; the top five players account for an estimated 38–44% of global revenue (HHI: 600–800). Competition centers on three strategic archetypes: integrated bearing OEMs expanding into sealing by acquisition, specialized isolator houses protecting niche technical leadership, and diversified fluid-handling conglomerates bundling isolators with pump packages.

  • Inpro/Seal (Waukesha Bearings): ~8–11% revenue share; CDM, VBX, and VBXX non-contacting isolators; pioneer of labyrinth bearing isolator seal technology with significant installed-base advantage.
  • Parker Hannifin: ~6–9% revenue share; PS Seal and Quick-Disconnect split isolators; broad fluid-power portfolio cross-sold to OEM pump builders. Acquired a European composite-seal manufacturer in January 2025 to expand additive-manufactured capacity for offshore wind.
  • Garlock (Enpro Industries): ~5–8% revenue share; Guardian and ISO-GARD bearing isolators; strong chemical-industry presence with split-design retrofit focus. Released ATEX-certified Zone 1 split-design kit in October 2024 for EU IED compliance.
  • SKF: ~5–8% revenue share; SPEEDI-SLEEVE and bearing protection kits; integrated bearing + seal bundling strategy. Announced VFD manufacturer partnership in July 2024 for co-developed shaft-grounding and bearing isolator integrated solutions.
  • Flowserve: ~4–7% revenue share; OEM-integrated isolators on ANSI and API pumps; captive aftermarket channel. Integrated non-contacting bearing isolator technology as standard across its ANSI and API 610 pump platforms in February 2024.
  • AESSEAL: ~2–4% revenue share; LabTecta and LabTecta ATEX bearing isolators; magnetic bearing isolator seal innovator. Opened a Chennai manufacturing facility in April 2024 under India’s PLI scheme..
  • Timken: ~3–6% revenue share; Revolvo and mounted-bearing isolator packages; industrial distribution strength with mining focus. Acquired a South American distributor in November 2023 to strengthen coverage in Brazil’s pre-salt FPSO fleet.
  • John Crane (Smiths Group): ~3–5% revenue share; bearing protection accessories for rotating equipment; mechanical-seal adjacency with strong refinery penetration.
  • Isomag Corporation: ~2–4% revenue share; specialist in permanent-magnet face-seal bearing isolator technology.
  • Elliott Group (Ebara): ~1–3% revenue share; OEM-spec isolators for turbocompressors; turbomachinery OEM integration.

Recent Industry Developments

  • Inpro/Seal (March 2025): Launched the VBXX-IoT bearing isolator with embedded vibration and temperature sensors for predictive-maintenance integration, targeting refinery centrifugal pump fleets.
  • Parker Hannifin (January 2025): Acquired a European composite-seal manufacturer to expand additive-manufactured labyrinth bearing isolator seal capacity for offshore wind applications.
  • Garlock (October 2024): Released an ATEX-certified split-design bearing isolator retrofit kit rated for Zone 1 hazardous areas, addressing EU IED compliance in chemical plants.
  • SKF (July 2024): Announced a strategic partnership with a major VFD manufacturer to co-develop integrated shaft-grounding and bearing isolator solutions for NEMA-frame motors.
  • S. EPA (September 2024): Published updated Method 21 guidance clarifying that bearing vapor emission from rotating equipment must be included in facility Leak Detection and Repair (LDAR) programs, strengthening the regulatory driver for bearing isolator adoption.
  • AESSEAL (April 2024): Opened a new manufacturing facility in Chennai, India, to localize production of magnetic bearing isolator seal units under the PLI scheme.
  • Flowserve (February 2024): Integrated non-contacting bearing isolator pump technology as a standard feature across its entire ANSI and API 610 pump platform, eliminating the optional-upgrade barrier.
  • Timken (November 2023): Acquired a South American distributor to strengthen aftermarket coverage for bearing isolator products in Brazil’s pre-salt FPSO fleet.

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com/reports/bearing-isolators-market-25228

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bearing Isolators Market to Reach USD 3.18 Billion at a 5.74% CAGR by 2035, Driven by VFD Proliferation, Fugitive-Emission Mandates, and ASEAN Manufacturing Expansion

Circuit Breaker Market Set for Robust Expansion Through 2035 Amid Grid Modernization Push, Renewable Energy Build-Out, and SF₆ Phase-Down Mandates

“Circuit Breaker Market Outlook”
Global Market Projected to Grow from USD 23.18 Billion in 2025 to USD 39.72 Billion by 2035, Registering a CAGR of 6.15% — Market Research Future

KEY MARKET FACTS AT A GLANCE

Market Size (2025): USD 23.18 Billion

Market Size (2026): USD 24.61 Billion

Market Size (2035): USD 39.72 Billion

CAGR (2026–2035): 6.15%

Fastest-Growing Technology: Solid-State Breakers at 9.4% CAGR

Fastest-Growing Voltage Segment: Extra/Ultra-High Voltage at 10.3% CAGR

Dominant End-User: Utilities — 41.0% of revenue (2024)

Fastest-Growing Region: Asia-Pacific at 7.2% CAGR (42.3% market share)

Study Period: 2021–2035

Market Overview

New York, NY – June 2, 2026 – The global Circuit Breaker Market reached an estimated USD 23.18 billion in 2025 and is projected to grow from USD 24.61 billion in 2026 to USD 39.72 billion by 2035, registering a CAGR of 6.15% over the forecast period, according to the latest industry analysis published by Market Research Future (MRFR). The report — “Circuit Breaker Market Size, Share & Growth Analysis Report — Trends & Industry Forecast to 2035” — covers segmentation by type, voltage, mounting, end user, and region.

Grid-modernization programs are a primary catalyst. The U.S. Bipartisan Infrastructure Law earmarks USD 65 billion for power-grid upgrades, and the Department of Energy’s Grid Resilience and Innovation Partnerships (GRIP) program has allocated USD 10.5 billion specifically for transmission and distribution upgrades — a large share of which flows into switchgear procurement (U.S. DOE, energy.gov/gdo/grid-resilience-and-innovation-partnerships-grip). Parallel investment in renewable-energy interconnection and industrial electrification is broadening the addressable base for advanced interruption devices.

Request for Free Sample PDF – https://www.marketresearchfuture.com/sample_request/921

Environmental regulation is reshaping product portfolios. The European Commission’s revised F-gas Regulation, published in April 2024, mandates a phase-down of SF₆ use in new medium-voltage switchgear from 2026, aiming to cut SF₆ deployment by 80% by 2030. Europe’s installed base of approximately 1.2 million SF₆-insulated switchgear panels represents a multi-billion-dollar retrofit opportunity for SF₆-free drop-in replacements (European Commission, climate.ec.europa.eu/eu-action/fluorinated-greenhouse-gases_en).

Key Market Drivers

  1. Grid Modernization & Aging Infrastructure Replacement

In Europe, the TEN-E regulation mandates cross-border grid reinforcement projects totaling an estimated EUR 584 billion through 2030, creating sustained demand for molded-case and vacuum circuit breakers at substations (European Commission, energy.ec.europa.eu/topics/infrastructure/trans-european-networks-energy_en). Utilities are replacing 30-to-40-year-old oil circuit breakers with modern vacuum and SF₆-free units offering digital monitoring, lower maintenance costs, and bidirectional-power-flow compatibility. Grid modernization and aging infrastructure replacement contributes an estimated +1.4% to overall market CAGR.

  1. Renewable-Energy Interconnection (Solar & Wind)

The International Energy Agency projects global renewable capacity additions of 560 GW annually through 2030, each gigawatt requiring multiple medium-voltage and high-voltage breaker installations at the point of interconnection (IEA, iea.org/reports/renewables-2024). India’s Revamped Distribution Sector Scheme (RDSS) alone targets 25 million smart meters and associated circuit breaker panel upgrades across distribution feeders, representing a procurement pipeline exceeding USD 3.2 billion (India Ministry of Power, powermin.gov.in). Renewable interconnection contributes an estimated +1.2% to market CAGR.

  1. Data-Center Campus Electrification

Hyperscale data-center operators are deploying campuses drawing 100–300 MW each, requiring redundant busway systems protected by molded-case circuit breaker assemblies rated for rapid fault isolation. The global data-center construction pipeline was estimated at USD 48 billion for 2025 alone — a direct catalyst for high-amperage, low-voltage circuit breaker procurement (Uptime Institute). Data-center electrification contributes an estimated +0.8% to market CAGR.

  1. EV Charging Infrastructure Rollout

The European Alternative Fuels Infrastructure Regulation (AFIR) mandates a fast-charging station every 60 km along TEN-T core corridors, with each station requiring dedicated residual-current circuit breaker protection against DC fault leakage (European Parliament, europarl.europa.eu). China’s charging-station count surpassed 3.1 million units in 2024, and the State Council plans to double that by 2027, generating substantial Circuit Breaker Market demand at the distribution-panel level. EV charging infrastructure rollout contributes an estimated +0.7% to market CAGR.

Browse Premium Research Insights with Latest Updates – https://www.marketresearchfuture.com/reports/circuit-breaker-market-921

Market Segmentation Highlights

By Type

  • Vacuum circuit breakers captured 36.6% of market revenue in 2024, reflecting strong adoption in medium-voltage switchgear replacement cycles.
  • Solid-state circuit breakers are forecast to expand at the fastest rate — a 9.4% CAGR through 2035 — propelled by data-center and HVDC deployments.
  • Air circuit breakers represented USD 3.47 billion in 2025 revenue, serving low-voltage distribution panels.
  • Oil circuit breakers accounted for USD 1.62 billion in 2025 revenue, driven by legacy installed bases in emerging markets.
  • Hybrid circuit breakers are growing at a 7.8% CAGR, favored in compact substation designs.
  • SF₆ circuit breakers carry a 5.1% CAGR as the technology transitions to eco-gas alternatives.

By Voltage Rating

  • Medium-voltage equipment held 39.1% of market revenue in 2024, underpinned by distributed solar and wind integration.
  • Low-voltage breakers represented USD 5.12 billion in 2025 revenue, driven by commercial buildings and residential panel upgrades.
  • High-voltage breakers are growing at a 6.4% CAGR, powered by transmission network upgrades.
  • Extra/ultra-high-voltage breakers are the fastest-growing voltage segment at a 10.3% CAGR, driven by UHVDC cross-border super-grid corridors. Per-unit values exceed USD 500,000 for 800 kV HVDC systems.

By End User

  • Utilities accounted for 41.0% of revenue in 2024, driven by multi-year transmission and distribution CAPEX programs in China, India, and Europe.
  • Industrial end users represented USD 5.28 billion in 2025 revenue, supported by process electrification and mining.
  • Commercial end users represented USD 3.94 billion in 2025 revenue, with data centers, retail, and healthcare as primary demand channels.
  • Residential demand is expanding at a 5.4% CAGR, driven by building-code mandates for arc-fault and earth-leakage protection in India, Australia, and the EU.

Regional Market Analysis

Asia-Pacific — Largest Region (42.3% Share, 7.2% CAGR)

Asia-Pacific holds 42.3% of global circuit breaker revenue, led by China’s State Grid Corporation and India’s RDSS program. China and India together contribute over 60% of regional demand. China’s State Grid Corporation planned USD 75 billion in CAPEX for 2024, a significant portion directed toward HVDC circuit breaker procurement for ±800 kV corridors linking western renewables to eastern load centers. India’s RDSS and Saubhagya electrification scheme are fueling demand for miniature circuit breaker panel assemblies at the last-mile distribution level (India Ministry of Power, powermin.gov.in). The miniature circuit breaker panel segment in Asia-Pacific is expected to grow at 7.2% CAGR through 2035.

Europe — 23.5% Share

Europe’s circuit breaker market is driven by offshore-wind grid connections and SF₆ phase-down retrofits. Germany accounts for 22.1% of the European region’s share, with the Energiewende program requiring an estimated EUR 110 billion in grid investment by 2030. The United Kingdom’s Contracts for Difference program is driving 50 GW of offshore-wind capacity requiring dedicated high-voltage breaker installations. France represented USD 1.18 billion in 2025 revenue, supported by nuclear fleet upgrades (European Commission, climate.ec.europa.eu).

North America — 20.8% Share

The United States accounts for the majority of North American revenue, with the DOE’s GRIP grants and Inflation Reduction Act channeling investment into grid-hardening and clean-energy interconnection (U.S. DOE, energy.gov/gdo/grid-resilience-and-innovation-partnerships-grip). The U.S. circuit breaker market is growing at a 7.2% CAGR. Canada represented USD 1.03 billion in 2025 revenue, driven by hydro-grid modernization at provincial utilities such as BC Hydro and Hydro-Québec.

Middle East & Africa — 6.2% Share

Saudi Arabia accounts for 31.4% of the MEA region’s share, driven by NEOM and Vision 2030 megaproject procurement orders for vacuum circuit breaker equipment and residual-current circuit breaker panels. South Africa’s Eskom recapitalization plan, backed by an international USD 8.5 billion Just Energy Transition Partnership, is accelerating replacement of end-of-life oil-filled switchgear (African Development Bank, afdb.org). Sub-Saharan Africa’s electrification rate remains below 50%, and the African Development Bank has committed USD 25 billion over ten years for grid extension and mini-grid projects, each requiring circuit breaker protection.

Ask for any Customization – https://www.marketresearchfuture.com/ask_for_customize/921

Key Market Participants

The global Circuit Breaker Market is moderately concentrated, with a CR5 estimated between 48% and 55%. Leading companies profiled in the report include:

  • ABB Ltd. — Estimated 10–14% revenue share; offerings include ADVAC vacuum, AirPlus eco-gas, and Emax solid-state breakers; digital-twin integration strategy (abb.com).
  • Siemens Energy — Estimated 9–13% revenue share; Blue GIS clean-air product line; commissioned a Berlin production line with 2,500-bay annual capacity in January 2025 (siemens-energy.com).
  • Schneider Electric — Estimated 8–12% revenue share; Masterpact MTZ, SM AirSeT, and EasyPact product lines; expanded India production for RDSS pipeline in October 2024 (se.com).
  • Eaton Corporation — Estimated 5–8% revenue share; Power Defense, Magnum DS, and VCP-W vacuum products; acquired a solid-state breaker start-up in July 2024 to enter the HVDC data-center segment (eaton.com).
  • Mitsubishi Electric — Estimated 5–7% revenue share; AE series MCCB and VCB for medium voltage; strong Asia-Pacific presence.
  • Hitachi Energy — Estimated 4–7% revenue share; HVDC specialization; delivered the world’s first ±525 kV HVDC breaker to Germany’s SuedOstLink project in February 2024 (hitachienergy.com).
  • GE Vernova — Estimated 4–6% revenue share; EntelliGuard and SecoVac product lines.
  • CG Power (Crompton Greaves) — Estimated 2–4% revenue share; India distribution-segment leader for indoor/outdoor vacuum circuit breaker and SF₆ panels.

Recent Industry Developments

  • ABB (March 2025): Launched the AirPlus 170 kV clean-air circuit breaker — the industry’s highest-rated SF₆-free unit — targeting European transmission operators.
  • Siemens Energy (January 2025): Commissioned a Blue GIS production line in Berlin with annual capacity of 2,500 bays, scaling SF₆-free manufacturing.
  • Schneider Electric (October 2024): Expanded SM AirSeT medium-voltage switchgear production in India to serve the RDSS upgrade pipeline.
  • Eaton Corporation (July 2024): Acquired a solid-state breaker start-up to accelerate entry into the HVDC circuit breaker segment for data-center applications.
  • European Commission (April 2024): Published revised F-gas Regulation mandating a scheduled phase-down of SF₆ in new medium-voltage switchgear from 2026.
  • Hitachi Energy (February 2024): Delivered the world’s first ±525 kV HVDC breaker to the SuedOstLink project in Germany.
  • India Ministry of Power (November 2023): Released RDSS Phase-II guidelines requiring smart MCB panel metering infrastructure across 250 distribution circles (powermin.gov.in).

Emerging Opportunities

  • HVDC Transmission Corridors: The segment is projected to exceed USD 2.8 billion by 2032 as European (North Sea Wind Power Hub) and Asian (China ±800 kV UHV lines) projects scale from pilot to commercial deployment.
  • Digital Twin & Breaker-as-a-Service: Utilities using condition-based monitoring on vacuum units have reported 20–30% reductions in unplanned outage costs, creating a recurring-revenue opportunity for OEMs.
  • Emerging-Market Rural Electrification: The African Development Bank’s USD 25 billion ten-year grid-extension commitment presents greenfield procurement channels (afdb.org).
  • S. Defense Microgrid Programs: The U.S. Department of Defense has earmarked USD 1.7 billion for energy-resilience upgrades across 130 installations, a significant portion expected to flow into solid-state breaker procurement (acq.osd.mil/eie/ie/FEP_Energy.html).
  • SF₆ Retrofit Market: Europe’s approximately 1.2 million SF₆-insulated switchgear panels represent a multi-billion-dollar retrofit opportunity for eco-gas drop-in replacements (European Commission).Other Related Pages:

 

Circuit Breaker MRO Services Market

Circuit Breaker for Equipment Market

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com/reports/circuit-breaker-market-921

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Circuit Breaker Market Set for Robust Expansion Through 2035 Amid Grid Modernization Push, Renewable Energy Build-Out, and SF₆ Phase-Down Mandates

Joshua Bredl: YETSKII, the Trainer Who Designed and Built Justin Bieber’s Gym Inside the Webby Award-Winning Compound, Launches Yeti Ultra on Father’s Day

The trainer who designed and built Justin Bieber’s gym opens his training platform at yetiultra.com on June 21

DENVER, CO – June 1, 2026 – Joshua Bredl, known as YETSKII, is the trainer who designed and built Justin Bieber’s gym inside the entertainer’s compound on the Universal Studios backlot. On Father’s Day, June 21, Bredl launches Yeti Ultra at yetiultra.com.

Bieber’s compound ran from October 2025 through spring 2026 as one of the most-watched live productions on Twitch. The channel won Webby Awards in 2026 for Best Livestream and Creator Launch or Drop. Bredl worked inside the compound as Bieber’s personal trainer throughout the full run. He designed the gym layout, built the full equipment list, and oversaw installation. Bieber trained in that gym on Twitch streams seen around the world.

Bredl was a founding trainer at Dogpound West Hollywood, the training facility behind some of the most recognized bodies in entertainment. He has trained Kelly Rowland, Ricky Martin, Vanessa Hudgens, and Adam Levine. He won WWE Tough Enough Season 6 on national television, earning a four-year contract with WWE. He is a 2014 NCAA Division II national football champion from CSU-Pueblo, where he earned his degree in Exercise Science and Sports Nutrition.

Alongside Yeti Ultra, Bredl co-founded Portal Health AI, a guided peptide optimization platform. Clients consult with human optimization coaches and nurses who build personalized protocols. Ace, their AI agent, is available around the clock for anything a client would rather work through on their own terms, in private. 80+ products. Free to join. Portal Health AI is live at portalhealth.ai.

Yeti Ultra launches Father’s Day, June 21, 2026. yetiultra.com.

Bredl is a father of two. He chose the date.

“The pain will guide you,” Bredl said.

About Joshua Bredl / Yeti Ultra

Joshua Bredl, known as YETSKII, is the trainer who designed and built Justin Bieber’s gym and the founder of Yeti Ultra, based in Denver, Colorado. He has trained Kelly Rowland, Ricky Martin, Vanessa Hudgens, Adam Levine, and Justin Bieber. A 2014 NCAA Division II national champion and WWE Tough Enough Season 6 winner, Bredl is also the co-founder of Portal Health AI, a guided peptide optimization platform: portalhealth.ai. yetiultra.com. Contact: apply@yetiultra.com

Media Contact
Company Name: Yeti Ultra
Contact Person: Joshua Bredl
Email: Send Email
City: Denver
State: CO
Country: United States
Website: yetiultra.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Joshua Bredl: YETSKII, the Trainer Who Designed and Built Justin Bieber’s Gym Inside the Webby Award-Winning Compound, Launches Yeti Ultra on Father’s Day